DX3

The DX3 cell line is a highly characterized human melanoma model derived from a metastatic site, offering researchers a robust platform for investigating the molecular mechanisms of tumor progression, epithelial-mesenchymal transition (EMT), and pharmacological resistance. As melanoma remains one of the most aggressive malignancies, the DX3 line serves as a critical tool for bridging the gap between basic oncogenic signaling research and preclinical drug development.

• Stable Metastatic Phenotype: Unlike early-stage primary melanoma lines, DX3 cells exhibit a stabilized metastatic profile. This makes them exceptionally suited for migration and invasion assays, as well as in vivo xenograft models to study organ-specific colonization.
• Well-Defined Genetic Background: Our DX3 cells are rigorously authenticated via STR profiling and characterized for key melanoma drivers. Their distinct mutational status provides a reliable baseline for studying MAPK pathway signaling (BRAF/MEK) and evaluating the efficacy of targeted kinase inhibitors.
• High Transfection Efficiency & Plasticity: DX3 cells demonstrate superior amenability to genetic manipulation, including CRISPR/Cas9 gene editing and lentiviral transduction. This plasticity allows for the rapid generation of reporter lines or knockout models to identify novel therapeutic targets.
• Optimized for High-Throughput Screening (HTS): With a consistent doubling time and predictable growth kinetics in standard DMEM/RPMI media, DX3 is an ideal candidate for large-scale small molecule libraries and toxicity profiling, ensuring high reproducibility across multi-well formats.

By incorporating the DX3 cell line into your oncology pipeline, you leverage a clinically relevant human model that provides the physiological depth necessary for high-impact cancer research and drug validation.